Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children

Human Vaccines

Volumn 7, Issue 4, 2011, Pages 451-457

  Sharma, Hitt J ^a   Yadav, Sangita ^b   Lalwani, Sanjay K ^a   Kapre, Subhash V ^a   Jadhav, Suresh S ^a   Chakravarty, Anita ^b   Parekh, Sameer S ^a   Palkar, Sonali ^a   Bhardwaj, Subodh H ^c   Namjoshi, Gajanan S ^c   Verma, Vikas ^b  

^a Bharati Vidyapeeth's Medical College   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

^c Earlier with Serum Institute of India Ltd   (India)

Author keywords

Booster dose; Immunogenicity; India; Indigenous; Safety; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; TRITANRIXHB; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DTWP HEPB HIB VACCINE; DTWP-HEPB-HIB VACCINE; HAEMOPHILUS VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ANAPHYLAXIS; ANOREXIA; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD CARE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYING; DIARRHEA; DIPHTHERIA; DROWSINESS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG HYPERSENSITIVITY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INDIAN; INFANT; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PAIN; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SKIN REDNESS; SWELLING; TERTIARY HEALTH CARE; TETANUS; VACCINE PRODUCTION; VOMITING; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; INDIA; METHODOLOGY; PRESCHOOL CHILD; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; INDIA; INFANT; MALE; VACCINATION;

EID: 79955022480     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.4.14208     Document Type: Article

References (29)

1. Nakayama T, Aizawa C, Kuno-Sakai H. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. J Allergy Clin Immunol 1999; 103:321-5. (Pubitemid 29095839)
2. Halsey N. Limiting infant exposure to thimerosal in vaccines and other sources of mercury. JAMA 1999; 282:763-6.
3. WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. November 2006. Weekly Epidemiological Record 81:445-52.
4. World Health Organisation. Geneva. Department of vaccines & biologicals. 2000. Introduction of Haemophilus type b vaccine into immunization programmes. Management guidelines, including information for healthworkers and parents.
5. Eskola J, Kayhty H, Gordon L, Hovi T, Stenvik M, Ronnberg P, et al. Simultaneous administration of Haemophilus influenzae type b capsular polysacharride-diptheria toxoid conjugate vaccine with routine diptheria-tetanus and pertussis and inactivated poliovirus vaccinations of childhood. Pediatr Infect Dis J 1998; 7:480-4.
6. Ferreccio C, Clemens J, Avendano A, Horwitz I, Flores C, Avila L, et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysacharride-tetanus-protein conjugate vaccine coadministered in the same syringe with diptheria-tetanus toxoids-pertussis vaccine at two-four and six months of age. Pediatr Infect Dis J 1991; 10:764-71.
7. Khin MW, Aye M, Htay H, Safary A, Bock H. Comparison of separate and mixed administration of DTPw-HBV and Hib vaccines: Immunogenicity and Reactogenicity Profiles. Int J Infect Dis 1997; 2:79-84. (Pubitemid 28117646)
8. Santos J, Amando M, Leon T, Rivera L, Gaitán M, Rio C, et al. DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children. Vaccine 2002; 15:1887-93. (Pubitemid 34242847)
9. Tregnaghi M, López P, Rocha C, Rivera L, Marie-Pierre D, Ricardo R, Schuerman L. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America. Rev Panam Salud Publica 2006; 19:179-88. (Pubitemid 44147374)
10. Scheifele D, Meekison W, Guasparini R, Roberts A, Barreto L, Thipphawong J, Wiltsey S. Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18 month old children. Vaccine 1995; 13:104-8.
11. Sharma H, Dutta A, Joshi S, Malik S, Bhardwaj S, Namjoshi G, Parekh S. Safety and immunogenicity of diphtheria-tetanus-pertussis vaccine and hepatitis B vaccine as a new tetravalent combination (DTwP/HB) administered alone and at separate sites (DTwP and HB) including comparison with standard commercially available combination vaccine in Indian infants 6-14 weeks of age. Hum Vaccin 2009; 5:310-4.
12. Sharma H, Multani A, Dutta A, Joshi S, Malik S, Bhardwaj S, et al. Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical Trials. Hum Vaccin 2009; 5:483-7.
13. World Health Organization. Department of vaccines & biologicals. Geneva 2000. Supplemental information on vaccine safety Part 2: Background rates of adverse events following immunization. WHO/V&B/00.36.
14. Aristegui J, Usonis V, Coovadia H, Riedemann S, Khin MW, Gatchalian S, Bock HL. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis 2003; 7:143-51. (Pubitemid 36753521)
15. th Interscience conference on Antimicrobial agents and Chemotherapy, San Francisco 1995; 17-20.
16. Bravo L, Carlos J, Gatchalian S, Borja TC, Bibera G, Willems P, et al. The new DTPw-HBV-Hib combination vaccine can be used at the WHO schedule with a monovalent dose of hepatitis B vaccine at birth. Southeast Asian J Trop Med Public Health 1998; 29:772-8. (Pubitemid 128709190)
17. Gatchalian S, Marietta R, Bernal N, Inge L, Marie- Pierre D, Htay HH, et al. A new DTPw-HBV/ Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin 2005; 5:198-203.
18. Lopez P, Luisa R, Maria R, Marie-Pierre D, Safary A. Immunogenicity and reactogenicity of DTPw-HB/Hib vaccine administered to Colombian infants after a birth dose of hepatitis B vaccine. Expert Rev. Vaccines 2002; 1:277-83. (Pubitemid 36559864)
19. Nolan T, Hogg G, Darcy MA. 18 m booster immunogenicity and reactogenicity in infants immunized with a combination DTPw-Hib-Hep B vaccine. Pediatr Res 1997; 41:128.
20. Riedemann S, Germán R, Jaime JJ, Richard RM, Wenzel MS, Paul W, Bock HL. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4, 6 months of age with a booster at 18 months. Int J Infect 2002; 6:215-22.
21. WHO position paper on Diphtheria vaccine. Wkly Epidemiol Rec 2006; 81:24-32.
22. WHO position paper on Tetanus vaccine. Wkly Epidemiol Rec 2006; 81:198-208.
23. WHO position paper on Hepatitis B vaccines. Wkly Epidemiol Rec 2004; 79:255-63.
24. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100. (Pubitemid 13068358)
25. World Health Organization. Position paper on Pertussis vaccines. Wkly Epidemiol Rec 2005; 80:31-9.
26. Recommendations for whole-cell pertussis vaccine. WHO Technical Report Series No. 941, 2007. Annex 6.
27. Kohl K, Walop W, Gidudu J, Ball L, Halperin S, Hammer S, et al. The Brighton Collaboration Local Reaction Working Group for Swelling at or near Injection Site. Swelling at or near injection site: Case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007; 25:5858-74.
28. Marcy S, Kohl K, Dagan R, Nalin D, Blum M, Jones M, et al. The Brighton Collaboration Fever Working Group. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis and presentation Vaccine 2004; 22:551-6.
29. Jones B, Javris P, Lewis J, Ebbutt. Trials to assess equivalence, importance of rigorous methods. BMJ 1996; 313:36-9.